Pub Date : 2024-02-23DOI: 10.1177/09733698241229949
A. Anuja, M. Rai, Latika Gupta, Neha Nigam, Vikas Agarwal
Majority of available protocols for isolation of chondrocytes from articular cartilage tissue rely on the enzymatic digestion of the tissue by collagenase type 2. The yield of chondrocytes in such protocols is low. Herein, we designed a novel indigenous sequential digestion by dual enzyme Pronase and Collagenase Type 1 for isolating human Chondrocytes from articular cartilage. Articular cartilage of Osteoarthritis (OA) patients undergoing total knee replacement were collected for the isolation of chondrocyte cells and subjected to sequential digestion by Pronase for three hours followed by Collagenase 1 overnight. Pellet of cells collected after digestion was plated on culture flask in 5% CO2 incubator. From day three onwards, round to elongated cells adhered to the flask were visible which developed into elongated cell population of homogenous morphology, expressed Aggrecan (Agg), Collagen 2a (Col2a) and SRY-box transcription factor (Sox9) and had chondrogenic differentiation similar to a commercially available healthy chondrocyte. These cells were negative for Alizarin red stain, thus confirming the purity of chondrocytes. We have successfully established a sequential dual enzyme digestion-based culture technique for isolating the human chondrocytes from the articular cartilage biopsy derived from OA knee joints.
{"title":"Dual Enzyme Sequential Digestion Protocol for Isolation of Human Primary Chondrocytes From the Articular Cartilage Derived From Knee Osteoarthritis Patients","authors":"A. Anuja, M. Rai, Latika Gupta, Neha Nigam, Vikas Agarwal","doi":"10.1177/09733698241229949","DOIUrl":"https://doi.org/10.1177/09733698241229949","url":null,"abstract":"Majority of available protocols for isolation of chondrocytes from articular cartilage tissue rely on the enzymatic digestion of the tissue by collagenase type 2. The yield of chondrocytes in such protocols is low. Herein, we designed a novel indigenous sequential digestion by dual enzyme Pronase and Collagenase Type 1 for isolating human Chondrocytes from articular cartilage. Articular cartilage of Osteoarthritis (OA) patients undergoing total knee replacement were collected for the isolation of chondrocyte cells and subjected to sequential digestion by Pronase for three hours followed by Collagenase 1 overnight. Pellet of cells collected after digestion was plated on culture flask in 5% CO2 incubator. From day three onwards, round to elongated cells adhered to the flask were visible which developed into elongated cell population of homogenous morphology, expressed Aggrecan (Agg), Collagen 2a (Col2a) and SRY-box transcription factor (Sox9) and had chondrogenic differentiation similar to a commercially available healthy chondrocyte. These cells were negative for Alizarin red stain, thus confirming the purity of chondrocytes. We have successfully established a sequential dual enzyme digestion-based culture technique for isolating the human chondrocytes from the articular cartilage biopsy derived from OA knee joints.","PeriodicalId":54167,"journal":{"name":"Indian Journal of Rheumatology","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2024-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140435916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-23DOI: 10.1177/09733698241229834
Girija Sachdev, A. Patankar, Bishakha Swain, Parimal Rathod, C. Balakrishnan
{"title":"Tofacitinib for Spondyloarthropathy Related Pubic Symphisitis","authors":"Girija Sachdev, A. Patankar, Bishakha Swain, Parimal Rathod, C. Balakrishnan","doi":"10.1177/09733698241229834","DOIUrl":"https://doi.org/10.1177/09733698241229834","url":null,"abstract":"","PeriodicalId":54167,"journal":{"name":"Indian Journal of Rheumatology","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2024-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140436855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-23DOI: 10.1177/09733698241231339
Smriti Gupta, M. Kumaran
Lupus erythematosus is an autoimmune disease characterised by the formation of various autoantibodies, leading to the involvement of numerous organ systems like the nervous system, renal system, and cutaneous involvement. Cutaneous involvement is the second most common manifestation after musculoskeletal involvement and can range from minor involvement to severe disabling sequelae. The type of skin manifestation can sometimes predict the underlying systemic involvement, as most patients of acute lupus erythematosus have concomitant systemic involvement in contrast to limited chronic cutaneous LE, which has a low incidence of systemic involvement. The cutaneous manifestations have been included in the Systemic Lupus International Collaborating Clinics (SLICC) and American College of Rheumatology criteria for ease in diagnosing lupus erythematosus patients. Herein, we present a review of various cutaneous manifestations seen in association with systemic lupus erythematosus (SLE) patients and their specific management, which can ease the early diagnosis of the patients and triage the patients that will need close follow-up for systemic involvement.
红斑狼疮是一种自身免疫性疾病，其特点是形成各种自身抗体，导致神经系统、肾脏系统和皮肤等多个器官系统受累。皮肤受累是仅次于肌肉骨骼受累的第二大常见表现，从轻微受累到严重致残的后遗症都有可能。皮肤表现的类型有时可以预示潜在的全身受累情况，因为大多数急性红斑狼疮患者都同时伴有全身受累，而局限性慢性皮肤LE的全身受累发生率较低。为了便于诊断红斑狼疮患者，皮肤表现已被纳入系统性红斑狼疮国际合作诊所（SLICC）和美国风湿病学会（American College of Rheumatology）的标准。在此，我们将综述系统性红斑狼疮（SLE）患者的各种皮肤表现及其具体的处理方法，以方便对患者进行早期诊断，并对需要密切随访以确定是否有系统性受累的患者进行分流。
{"title":"Skin Changes in Lupus Erythematosus: A Concise Review Lupus Erythematosus and Skin-demystifying the Features","authors":"Smriti Gupta, M. Kumaran","doi":"10.1177/09733698241231339","DOIUrl":"https://doi.org/10.1177/09733698241231339","url":null,"abstract":"Lupus erythematosus is an autoimmune disease characterised by the formation of various autoantibodies, leading to the involvement of numerous organ systems like the nervous system, renal system, and cutaneous involvement. Cutaneous involvement is the second most common manifestation after musculoskeletal involvement and can range from minor involvement to severe disabling sequelae. The type of skin manifestation can sometimes predict the underlying systemic involvement, as most patients of acute lupus erythematosus have concomitant systemic involvement in contrast to limited chronic cutaneous LE, which has a low incidence of systemic involvement. The cutaneous manifestations have been included in the Systemic Lupus International Collaborating Clinics (SLICC) and American College of Rheumatology criteria for ease in diagnosing lupus erythematosus patients. Herein, we present a review of various cutaneous manifestations seen in association with systemic lupus erythematosus (SLE) patients and their specific management, which can ease the early diagnosis of the patients and triage the patients that will need close follow-up for systemic involvement.","PeriodicalId":54167,"journal":{"name":"Indian Journal of Rheumatology","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2024-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140436330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-23DOI: 10.1177/09733698241229743
U. Dhakad, P. Mehta, K. Kishor
Peripheral ischemic lesions in rheumatic diseases have variable presentations, prognoses and outcomes that have not been well studied in published literature. The present study aimed to investigate the clinical presentation, aetiology, prognosis and outcomes of peripheral ischemic lesions in rheumatic diseases. A medical records review of all patients who presented with peripheral ischemic lesions was conducted in the Department of Clinical Immunology and Rheumatology of a tertiary care institution in Northern India. Data from March 2013 to December 2017 was collected in the form of demographic and clinical details, investigations, treatment and outcomes. Of 103 patients that presented with peripheral ischemic lesions, 80 (77.6%) had an underlying rheumatic disease. In the group with rheumatic causes, the mean age was 29.31 years, and the majority (87%) presented in the winter season. The most common rheumatic cause was vasculitis (55%) followed by systemic sclerosis (17.5%), systemic lupus erythematosus (15%) and primary antiphospholipid antibody syndrome (6, 7.5%). Amputation (either surgical or auto-amputation) was observed in 55% of the cases, while the remaining recovered completely or near completely with medical treatment. Peripheral ischemic lesions may present as the initial or predominant manifestation of rheumatic disease with vasculitis being the most common cause. Late referral or presentation to the hospital, delayed specific management and presentation as gangrene resulted in poorer outcomes in these patients.
{"title":"Early Recognition and Institution of Treatment is Associated with a Good Prognosis in Peripheral Ischemic Lesions in Rheumatic Diseases","authors":"U. Dhakad, P. Mehta, K. Kishor","doi":"10.1177/09733698241229743","DOIUrl":"https://doi.org/10.1177/09733698241229743","url":null,"abstract":"Peripheral ischemic lesions in rheumatic diseases have variable presentations, prognoses and outcomes that have not been well studied in published literature. The present study aimed to investigate the clinical presentation, aetiology, prognosis and outcomes of peripheral ischemic lesions in rheumatic diseases. A medical records review of all patients who presented with peripheral ischemic lesions was conducted in the Department of Clinical Immunology and Rheumatology of a tertiary care institution in Northern India. Data from March 2013 to December 2017 was collected in the form of demographic and clinical details, investigations, treatment and outcomes. Of 103 patients that presented with peripheral ischemic lesions, 80 (77.6%) had an underlying rheumatic disease. In the group with rheumatic causes, the mean age was 29.31 years, and the majority (87%) presented in the winter season. The most common rheumatic cause was vasculitis (55%) followed by systemic sclerosis (17.5%), systemic lupus erythematosus (15%) and primary antiphospholipid antibody syndrome (6, 7.5%). Amputation (either surgical or auto-amputation) was observed in 55% of the cases, while the remaining recovered completely or near completely with medical treatment. Peripheral ischemic lesions may present as the initial or predominant manifestation of rheumatic disease with vasculitis being the most common cause. Late referral or presentation to the hospital, delayed specific management and presentation as gangrene resulted in poorer outcomes in these patients.","PeriodicalId":54167,"journal":{"name":"Indian Journal of Rheumatology","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2024-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140438159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-23DOI: 10.1177/09733698241229936
Taral Parikh, S. Yadav, C. Balakrishnan
To study the clinical and serological predictors of radiological progression at one year in a cohort of Indian patients with early rheumatoid arthritis (RA). In this prospective open-label observational study, consecutive patients with early RA (
{"title":"Radiological Progression and Predictors of Radiological Progression in Early Rheumatoid Arthritis Treated with Conventional Synthetic Disease-modifying Agents","authors":"Taral Parikh, S. Yadav, C. Balakrishnan","doi":"10.1177/09733698241229936","DOIUrl":"https://doi.org/10.1177/09733698241229936","url":null,"abstract":"To study the clinical and serological predictors of radiological progression at one year in a cohort of Indian patients with early rheumatoid arthritis (RA). In this prospective open-label observational study, consecutive patients with early RA (<six months) were examined at baseline and at each visit (0, 3, 6, 9 and 12 months) for disease activity, DAS ESR 28 and European League Against Rheumatism response. Radiography of the hands and feet was performed at baseline and at one year of treatment, and radiologic progression was assessed using van der Heijde’s Sharp score. The prognostic factors were evaluated using a logistic regression model. Fifty-one eligible patients were analysed for disease outcomes, whereas 43 were eligible for radiographic progression. The mean duration of RA was 3.4 ± 1.85 months. At baseline, 96% of the patients had moderate to high disease activity. The proportion of patients with erosions increased from 16.3% to 37.2% at one year, whereas that of patients with joint space narrowing (JSN) increased from 21% to 39.5%. At one year, the mean increase in total Sharp’s score was 1.67, while 32.5% of patients had radiological progression. Age of onset, presence of erosions, JSN, anticitrullinated protein antibody (ACPA) titre and tender joint counts at baseline were associated with radiographic progression at one year. However, in the multivariate analysis, none of the variables predicted radiographic damage. Only JSN was positively associated with progression at one year. Age at onset, presence of erosions, JSN, ACPA titre and tender joint counts at baseline were associated with radiographic progression at one year, but further studies are required to confirm these results.","PeriodicalId":54167,"journal":{"name":"Indian Journal of Rheumatology","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2024-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140435481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-23DOI: 10.1177/09733698241231334
K. Hazarika, J. Dixit, Nishant Kamble, U. Dhakad
{"title":"Recurrent Autoimmune Haemolytic Anaemia or Diffuse Alveolar Haemorrhage? A Diagnostic Dilemma in a Case of Childhood SLE","authors":"K. Hazarika, J. Dixit, Nishant Kamble, U. Dhakad","doi":"10.1177/09733698241231334","DOIUrl":"https://doi.org/10.1177/09733698241231334","url":null,"abstract":"","PeriodicalId":54167,"journal":{"name":"Indian Journal of Rheumatology","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2024-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140437715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-23DOI: 10.1177/09733698241229905
K. Chandwar, Abilash Krishnan Vijayakumaran, K. Kishor, P. Dogga, J. Dixit, D. Ekbote, Puneet Kumar, U. Dhakad
To assess causes of vaccine hesitancy to COVID-19 vaccines in patients with autoimmune rheumatic diseases (AIRD). Study design: We conducted a cross-sectional observational survey-based study of patients attending Rheumatology OPD regarding the reason for vaccine hesitancy, counselled by treating rheumatologists and responses regarding willingness recorded after counselling. Convenience sampling was done by including all adults (>18 years) with AIRD attending rheumatology OPD. Those vaccinated, recently infected (within six weeks), and non-AIRD patients were excluded. The questionnaire included details about patients’ demography, medication and reason for vaccine hesitancy. Statistical analysis was performed using measures of central tendency for quantitative variables and using counts and percentages for qualitative variables. A total of 322 patients participated in the study with a mean age of 40 years (18–76), with 73% (234) females and 27% (88) males. Most patients had RA (40%) followed by SpA (27%), SLE (13%) and were on immunosuppressive medications (95%). A significant proportion of patients (60%) had more than one reason for vaccine hesitancy. Almost 60% of the respondents feared disease flare post-vaccination, while almost half (44.4%) feared vaccine side effects and more than one-third (35%) doubted vaccine efficacy while on immunosuppressive medications. Other causes were the inability to get vaccinated (18%), doubts about vaccine efficacy (15%), and fear of injections (10%). Most patients (91%) expressed vaccine acceptance after specialist counselling. Vaccine hesitancy is multifactorial. Addressing reasons for vaccine hesitancy in patients with AIRD like fear of flare of disease post-vaccination, fear of vaccine side effects and doubts over vaccine efficacy while taking immunosuppressive medications are necessary. Most patients were willing to take vaccine after counselling by a rheumatologist.
{"title":"Vaccine Hesitancy Against COVID-19 Vaccines in Patients with Autoimmune Rheumatic Diseases and Effect of Specialist Counselling on Vaccine-hesitant Patients","authors":"K. Chandwar, Abilash Krishnan Vijayakumaran, K. Kishor, P. Dogga, J. Dixit, D. Ekbote, Puneet Kumar, U. Dhakad","doi":"10.1177/09733698241229905","DOIUrl":"https://doi.org/10.1177/09733698241229905","url":null,"abstract":"To assess causes of vaccine hesitancy to COVID-19 vaccines in patients with autoimmune rheumatic diseases (AIRD). Study design: We conducted a cross-sectional observational survey-based study of patients attending Rheumatology OPD regarding the reason for vaccine hesitancy, counselled by treating rheumatologists and responses regarding willingness recorded after counselling. Convenience sampling was done by including all adults (>18 years) with AIRD attending rheumatology OPD. Those vaccinated, recently infected (within six weeks), and non-AIRD patients were excluded. The questionnaire included details about patients’ demography, medication and reason for vaccine hesitancy. Statistical analysis was performed using measures of central tendency for quantitative variables and using counts and percentages for qualitative variables. A total of 322 patients participated in the study with a mean age of 40 years (18–76), with 73% (234) females and 27% (88) males. Most patients had RA (40%) followed by SpA (27%), SLE (13%) and were on immunosuppressive medications (95%). A significant proportion of patients (60%) had more than one reason for vaccine hesitancy. Almost 60% of the respondents feared disease flare post-vaccination, while almost half (44.4%) feared vaccine side effects and more than one-third (35%) doubted vaccine efficacy while on immunosuppressive medications. Other causes were the inability to get vaccinated (18%), doubts about vaccine efficacy (15%), and fear of injections (10%). Most patients (91%) expressed vaccine acceptance after specialist counselling. Vaccine hesitancy is multifactorial. Addressing reasons for vaccine hesitancy in patients with AIRD like fear of flare of disease post-vaccination, fear of vaccine side effects and doubts over vaccine efficacy while taking immunosuppressive medications are necessary. Most patients were willing to take vaccine after counselling by a rheumatologist.","PeriodicalId":54167,"journal":{"name":"Indian Journal of Rheumatology","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2024-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140436054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-23DOI: 10.1177/09733698241229746
Nikunjkumar V. Dadhaniya, S. Upadhyaya, S. Gupta, Rohini Handa
{"title":"Correspondence on ‘Detection and Correlation of Changes on Perimetry and Optical Coherence Tomography in Patients on Chronic Usage of Hydroxychloroquine: A Cross-sectional Study’","authors":"Nikunjkumar V. Dadhaniya, S. Upadhyaya, S. Gupta, Rohini Handa","doi":"10.1177/09733698241229746","DOIUrl":"https://doi.org/10.1177/09733698241229746","url":null,"abstract":"","PeriodicalId":54167,"journal":{"name":"Indian Journal of Rheumatology","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2024-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140436307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-23DOI: 10.1177/09733698241229803
Neha Singh, M. Rai, V. Agarwal, Vikas Agarwal
Systemic sclerosis (SSc) is a chronic disorder, characterised by endothelial dysfunction and fibrosis of skin and internal organs. Endothelium dysfunction leads to a decrease in nitric oxide levels, consequent to reduced Nitric Oxide synthase 3 (NOS3) activity due to decreased NOS3 gene function. Besides endothelium, macrophages too play an important role in the pathogenesis of SSc; classically activated M1 macrophages (express NOS2) and alternatively activated M2 macrophages (express Arginase1) are differentially altered in favour of M2 macrophages. Micro-RNAs (miRNAs) regulate expression of various genes and may favour disease phenotype. Our aim was to identify differentially expressed micro-RNAs in SSc, which target NOS2, NOS3 and Arginase1 genes by in-silico approach. Data on miRNAs upregulation reported in various studies was collected and their sequence ID from miRBase was identified in FASTA format from NCBI. Binding strength of these miRNAs against NOS2, NOS3 and Arginase1 genes was evaluated by RNA22. After scanning 39 publications reporting miRNA expression in SSc, a total of 13 miRNAs were found to be up-regulated for NOS2 (Gibbs free energy ≤18.0Kj/mol) and 15 miRNAs up-regulated for NOS3 (Gibbs free energy ≤18.0Kj/mol) whereas for Arginase1 only 2 miRNAs were up-regulated. There is differential upregulation of miRNAs in SSc. Micro RNAs targeting NOS2 and NOS3 genes are highly up-regulated in comparison to Arginase 1. Role of epigenetic regulation of genes by miRNAs may play a key role in pathogenesis of SSc.
{"title":"In Silico Prediction of NOS2, NOS3 and Arginase 1 Genes Targeting by Micro RNAs Upregulated in Systemic Sclerosis","authors":"Neha Singh, M. Rai, V. Agarwal, Vikas Agarwal","doi":"10.1177/09733698241229803","DOIUrl":"https://doi.org/10.1177/09733698241229803","url":null,"abstract":"Systemic sclerosis (SSc) is a chronic disorder, characterised by endothelial dysfunction and fibrosis of skin and internal organs. Endothelium dysfunction leads to a decrease in nitric oxide levels, consequent to reduced Nitric Oxide synthase 3 (NOS3) activity due to decreased NOS3 gene function. Besides endothelium, macrophages too play an important role in the pathogenesis of SSc; classically activated M1 macrophages (express NOS2) and alternatively activated M2 macrophages (express Arginase1) are differentially altered in favour of M2 macrophages. Micro-RNAs (miRNAs) regulate expression of various genes and may favour disease phenotype. Our aim was to identify differentially expressed micro-RNAs in SSc, which target NOS2, NOS3 and Arginase1 genes by in-silico approach. Data on miRNAs upregulation reported in various studies was collected and their sequence ID from miRBase was identified in FASTA format from NCBI. Binding strength of these miRNAs against NOS2, NOS3 and Arginase1 genes was evaluated by RNA22. After scanning 39 publications reporting miRNA expression in SSc, a total of 13 miRNAs were found to be up-regulated for NOS2 (Gibbs free energy ≤18.0Kj/mol) and 15 miRNAs up-regulated for NOS3 (Gibbs free energy ≤18.0Kj/mol) whereas for Arginase1 only 2 miRNAs were up-regulated. There is differential upregulation of miRNAs in SSc. Micro RNAs targeting NOS2 and NOS3 genes are highly up-regulated in comparison to Arginase 1. Role of epigenetic regulation of genes by miRNAs may play a key role in pathogenesis of SSc.","PeriodicalId":54167,"journal":{"name":"Indian Journal of Rheumatology","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2024-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140438004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-19DOI: 10.1177/09733698241229747
Kallur Sailaja Devi, Anisha Satish Shah, S. Tarakeswari, Madapu Manokanth, G. Usha
Takayasu’s arteritis (TA) is a rare medical disorder of probable immune aetiology which complicates pregnancy. It affects younger women predominantly and may have a significant impact on maternal and foetal health. To study the maternal and perinatal outcomes among pregnant women with TA, attending a dedicated obstetric hospital in South India. It is a retrospective observational study done at Fernandez Hospital, Hyderabad, with 10,000 births per annum. All women with TA-complicating pregnancies who were birthed from 2005 to 2022 were included. American College of Rheumatology criteria were used for the diagnosis of TA. The primary outcome of interest was to analyse the type of TA, maternal and foetal outcomes in pregnant women with TA. The secondary outcome of interest was to compare foetal outcomes between pregnancies managed at Fernandez Hospital (group A) versus previous pregnancies managed elsewhere (group B). During the study period, there were 119,053 births of which 38 women had TA, with a total of 92 pregnancies, of which 59 pregnancies were in group A and 33 pregnancies in group B. Type 4 was the commonest seen in 44% of women. Hypertensive disorders of pregnancy were seen in 67.7% of women. The live birth rate was 84%, miscarriages were 10% and 5% of women had stillbirths. Caesarean section rate was 59.3%. There was one maternal mortality. TA should be considered in young women with secondary hypertension. Maternal and foetal outcomes are good with appropriate diagnosis, treatment and management of complications.
高安氏动脉炎（TA）是一种罕见的内科疾病，其病因可能与免疫有关，会导致妊娠并发症。它主要影响年轻女性，可能对孕产妇和胎儿的健康产生重大影响。研究对象是在印度南部一家专科产科医院就诊的 TA 孕妇的孕产妇和围产期结局。这是一项在海德拉巴费尔南德斯医院进行的回顾性观察研究，该医院每年接生 10,000 例新生儿。研究纳入了 2005 年至 2022 年期间所有患有 TA 并发症的孕妇。美国风湿病学会标准用于 TA 的诊断。主要研究结果是分析TA孕妇的TA类型、母体和胎儿结局。次要研究结果是比较在费尔南德斯医院接受治疗的孕妇（A组）与之前在其他医院接受治疗的孕妇（B组）的胎儿结局。在研究期间，共有 119 053 名新生儿出生，其中 38 名妇女患有妊娠高血压，共 92 次妊娠，其中 59 次妊娠属于 A 组，33 次妊娠属于 B 组。67.7%的妇女患有妊娠高血压疾病。活产率为 84%，流产率为 10%，死胎率为 5%。剖腹产率为 59.3%。有一名产妇死亡。继发性高血压的年轻妇女应考虑使用 TA。通过适当的诊断、治疗和并发症处理，产妇和胎儿的预后良好。
{"title":"Maternal and Perinatal Outcomes in Pregnant Women with Takayasu’s Arteritis: 10 Years Retrospective Study at Tertiary Centre in South India","authors":"Kallur Sailaja Devi, Anisha Satish Shah, S. Tarakeswari, Madapu Manokanth, G. Usha","doi":"10.1177/09733698241229747","DOIUrl":"https://doi.org/10.1177/09733698241229747","url":null,"abstract":"Takayasu’s arteritis (TA) is a rare medical disorder of probable immune aetiology which complicates pregnancy. It affects younger women predominantly and may have a significant impact on maternal and foetal health. To study the maternal and perinatal outcomes among pregnant women with TA, attending a dedicated obstetric hospital in South India. It is a retrospective observational study done at Fernandez Hospital, Hyderabad, with 10,000 births per annum. All women with TA-complicating pregnancies who were birthed from 2005 to 2022 were included. American College of Rheumatology criteria were used for the diagnosis of TA. The primary outcome of interest was to analyse the type of TA, maternal and foetal outcomes in pregnant women with TA. The secondary outcome of interest was to compare foetal outcomes between pregnancies managed at Fernandez Hospital (group A) versus previous pregnancies managed elsewhere (group B). During the study period, there were 119,053 births of which 38 women had TA, with a total of 92 pregnancies, of which 59 pregnancies were in group A and 33 pregnancies in group B. Type 4 was the commonest seen in 44% of women. Hypertensive disorders of pregnancy were seen in 67.7% of women. The live birth rate was 84%, miscarriages were 10% and 5% of women had stillbirths. Caesarean section rate was 59.3%. There was one maternal mortality. TA should be considered in young women with secondary hypertension. Maternal and foetal outcomes are good with appropriate diagnosis, treatment and management of complications.","PeriodicalId":54167,"journal":{"name":"Indian Journal of Rheumatology","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2024-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140449681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：